Author Archives: admin


Stem cell industry ready to liftoff

By Gu Yang

According to statistics, up to August 1st, 2013, clinical trials on stem cell research publicly registered on the website of Clinical Trial have reached 4704, among which 213 were from China. Though it is far from 2805 of the US, Xu Xiaochun, the director of INCOSC and founder of Boya Life, insists that gap between China and developed countries in stem cell research field is not big -- "we are almost starting at the same time, since the key technology of stem cell has just got breakthrough in recent two or three years, and the development history of the whole industry is just 20 years."

"This is an original contribution in science which is most likely to be accomplished by China!" Xu Xiaochun stated briefly. The next few years will be the critical period for the development of global stem cell industry, and China is not to miss this valuable but fleeting opportunity.

A "gold mine" of USD400 billion is to be discovered

Who will be the next Microsoft? Even Gates himself admits that this company will surely come from the field of biological medicine, and it has been a consensus in the industry that stem cell industry is one of the cores and the most promising modules in the field of biological medicine.

In global market, stem cell technology and its development has been crazily pursued by international capital market in recent years, and relevant market value of stem cell concept stocks listed in NASDAQ only has exceeded USD30 billion. It is predicted by experts that the potential market of global stem cell industry will be about USD80 billion within the next two years, and reach up to USD400 billion around 2020.

In China, the stem cell industry also has bright prospects. According to the research reports from the institution named First Capital, the stem cell industry of China has formed a complete industry chain from the upstream storage to the downstream clinical application, and it is predicted that the income of stem cell industry in the coming 5 years will increase to RMB 30 billion from the current RMB 2 billion, at the average annual growth rate of 170 percent.

For many people, the stem cell, with the ability to repair and generate all human cells, has not been a strange concept. However, there are still some widespread misunderstandings in society about the cognition of stem cells in clinical application.

"Stem cell application doesn't only mean the storage of stem cells, but it has many downstream applications. Moreover, stem cells can also be used as a tool for new medicine research and development as well as other personalized medicine." Xu Xiaochun told the journalist that, Boya Life, founded by him, is such a group starting from stem cell research, turns the view to the whole field of biological economy while constantly extending upstream and downstream on the industry chain.

Continue reading here:
Stem cell industry ready to liftoff

How saving their baby teeth could help save children’s lives

Yorkshire (PRWEB UK) 21 January 2014

Ongoing worldwide research is consistently proving that stem cells will be a cornerstone of medical treatments in the future. Already, literally thousands of stem cell therapies for a host of dangerous and life-threatening conditions have already been successfully performed, and specialists agree that many newly discovered treatments are just around the corner.

Stem cells are biological cell types found in multicellular organisms like mammals, and that, of course, includes us. The incredible thing about stem cells is that they are able to divide and change into other types of cell, and this is what gives them their unique ability to repair, or even replace, cells that have been damaged by disease or injury.

The potential for the health of younger and future generations is enormous.

Although stem cells are found in many different parts of our body, it is the stem cells found in our childrens teeth that are most precious in terms of their potential to safeguard health. While an inevitable crystallisation process makes adult teeth useless for stem cell therapies, first teeth and young wisdom teeth contain tooth pulp in perfect condition to provide useable stem cells. Whats more, children naturally lose 12 milk teeth over a 5-year period, and this means plenty of chances to collect the teeth most likely to be suitable for harvesting stem cells. The other big advantage of childrens teeth is that they fall out naturally, and that makes recovering the teeth a pain-free, risk-free and non-invasive process.

Today, scientists have the expertise and technologies to safely extract and store stem cells taken from baby teeth and wisdom teeth. Crucially, storing a persons stem cells for possible use in their own future medical treatment means that compatibility or finding the right match wont ever be an issue. This is one of the key factors that has given rise to people storing their own childrens cells as a way of protecting them against a future illnesses or conditions. Having access to a childs stem cells makes any future treatment far more likely to succeed, an extremely encouraging situation given that scientists are regularly discovering more and more conditions they can treat using stem cells.

So, what about the specific illnesses and conditions that tooth stem cells can be used to treat?

Scientists already know that stem cells within tooth pulp have the ability to develop into a wide range of tissues, including skin, nerve, muscle, fat, cartilage and tendon. This amazing versatility has huge and positive implications for medical uses of tooth stem cells, and thats why almost everyone has a vested interest in this medical breakthrough, from young adults, parents and expectant parents right through to those who might one day want a family.

Stem cell therapy has already enabled practitioners to grow skin, tracheas and corneas, as well as repair human hearts. Even more excitingly, it is now widely agreed that future stem cell therapies will allow medical practitioners to tackle a host of injuries, illnesses and heredity conditions. Among them, these are likely to include Type 1 diabetes; neuronal degenerative disorders like Alzheimers, Parkinsons and Huntingtons disease; cardiovascular disease; paralysis due to spinal cord injury; liver disease, strokes; heart attacks and joint repair. Stem cells can also help to repair the bodys immune system and, under the right conditions, can even be used to form organs, bone and other tissue.

BioEden have a UK team that has been right at the very heart of the science surrounding the extraction and storage of tooth cells in fact they are one of the worlds leading authorities on it.

Follow this link:
How saving their baby teeth could help save children’s lives

Stem Cell Treatment – Stem Cell Therapy – Stem Cell …

Stem Cell Therapy

Stem cell treatment and stem cell therapy may be considered controversial and are, perhaps, viewed as akin to science fiction by some people. However, stem cell treatments have been used regularly in veterinary practice since 2003 for the repair of bone and tissue damage, and have a wealth of research highlighting their efficacy in both humans and other animals. Stem cells are found in plentiful supply in embryonic tissue, but are also found in adult tissues. These cells have the ability to self-renew, giving rise to countless generations of new cells with varying abilities to differentiate into specific cell types. By introducing stem cells into an area of damage or pathology, the body can be encouraged to repair and renew regardless of how old the trauma is. Stem cells also show application for inhibiting the death of cells (apoptosis) through disease, making them candidates for use in treating degenerative illnesses such as Lou Gehrigs disease, Multiple Sclerosis, Parkinsons disease and Alzheimers.

Stem cells from embryos are considered more flexible in terms of their ability to become either new liver cells, new neurons, new skin cells, and so on, whereas adult stem cells tend to be more restricted to the tissue type from which they were taken. New research is showing that this might not necessarily have to remain the case however, with the plasticity of adult stem cells now under investigation. Stem cell use carries little risk of the resulting tissues being rejected, it appears safe, efficient, and almost endless in its possibilities for application.

Potential Stem Cell Treatments

Conditions such as cardiovascular disease, diabetes, spinal cord injury, and cancer, among others, are considered possible candidates for stem cell treatment. Cures for some of these diseases could be closer than previously thought with clinical trials already showing impressive results where stem cells have been used in cases thought intractable. The rapid rate of progression in research and clinical use means that some of the controversial issues, such as the use of embryos as a source of stem cells, have been overcome, with governments around the globe subtly altering their legal policies in order to accommodate new scientific advances. In the US, Bill Clinton was the first president to have to consider the legal issues surrounding stem cells, and subsequent presidents have been forced to readdress the issues time and again in line with medical discoveries. Worldwide, governments have remained generally cautious over the use of this technology but are gradually improving funding access, whilst keeping an eye on the ethics of stem cell treatment, in order to explore the tremendous benefits that appear possible. The credibility of research remains a concern, with some stem cell studies discredited by ethics committees after initial general acceptance of their veracity.

Stem cells may be garnered from living adult donors and, indeed, already are in the case of bone marrow transplants. More usually they are taken from discarded embryos leftover after IVF treatment, or from the placenta after birth. Previously the removal of stem cells resulted in the destruction of these embryos, but now it is possible for scientists to remove the stem cells without this occurring. This development negates some of the criticism faced by the technology from religious groups and ethical bodies over the sanctity of life and the attribution of sentience and autonomy to embryos, gametes, and the foetus. Clearly, some debate remains about these issues in relation to stem cell research, but recent improvements in methodology may remove the need for these considerations completely. Clinicians have demonstrated the possibility of taking adult stem cells and seemingly teaching them to become cells of a different type to their site of removal, effectively returning them to a similar state to that of the embryonic stem cell. Whilst stem cells from embryos remain more reliable and more economical to work with, the use of adult tissue-derived stem cells could revolutionize the research in this field.

As well as stem cell use in pathology and disease, there are also applications in personal aesthetics such as the regeneration of hair follicles and an end to baldness through stem cell treatment. Stem cells are also considered useful in regenerating the skin after injury, without the scarring usually associated with repair. There are reports of paralyzed patients becoming mobile after years in a wheelchair through the use of stem cells injected into the spinal cord, and the rapid disappearance of tumors in brain tissue after stem cells were injected.

Stem cell treatment provides an exciting possibility to change the face of modern medicine, alleviating pain and suffering, and improving the prognosis for millions withe diseases previously thought incurable.

See more here:
Stem Cell Treatment – Stem Cell Therapy – Stem Cell ...

Stem Cell Therapies for Celiac Disease and IBD Now Offered in the United States

Tampa, FL (PRWEB) January 21, 2014

Regenerative Medicine Solutions (RMS), a global provider of stem cell treatments for degenerative diseases, is now offering Regenerative ColoTherapy (RCT), a proprietary stem cell treatment for people suffering with celiac and inflammatory bowel disease (IBD). Crohns disease and ulcerative colitis (UC) are two of the most notable conditions that fall under the IBD umbrella, affecting millions of people across the United States and the world.

It is estimated that there are 1.4 million cases of Crohns and colitis in the United States, which roughly translates to the population size of Philadelphia. Although Crohns, colitis, and celiac disease are very different conditions, affecting different areas of the intestines, treatment options are similar and mainly consist of diet modification, anti-inflammatories, and immunosuppressants.

In severe cases, sufferers use the restroom over 20 times a day and may require surgery to remove part of their intestine or colon. As you can imagine, symptoms of these disorders take a heavy toll on sufferers quality of life. Andrew, a 26-year-old RMS patient that suffers from ulcerative colitis underwent the Regenerative ColoTherapy.

For three years, I suffered from diarrhea, bleeding, painful stomach cramping, and being completely drained of energy, Andrew said. 90 days following the RCT procedure, I noticed considerable improvements in my symptoms. My bowel movements went from upwards of 20 times a day to less than five. This procedure was invaluable and in my opinion the best option for treating this disease.

As stem cells have the ability to differentiate into many different types of tissues and have been found to be immunomodulatory and anti-inflammatory in nature, their intrinsic healing capacity is highly beneficial for sufferers of celiac disease and IBD. RMS has harnessed the natural properties of stem cells in the form of Regenerative ColoTherapy, a unique stem cell treatment that utilizes stem cells from a patients own body for the regeneration and repair of damaged tissues in the intestines and colon.

Regenerative ColoTherapy treatments are being performed RMSs headquarters in Tampa, FL where it also operates its subsidiary company Lung Institute. To learn more about RCT or to schedule a free consultation call today at 1-855-469-5864.

About Regenerative Medicine Solutions

Regenerative Medicine Solutions (RMS) is a leading global provider of stem cell treatments for the treatment of an array of debilitating medical conditions. Notably, RMS performs Regenerative ColoTherapy an innovative treatment for people with celiac disease and IBD. For more information, visit MyRegenMed.com or call us today at 1-855-469-5864.

See the rest here:
Stem Cell Therapies for Celiac Disease and IBD Now Offered in the United States

Pluristem Gains Most in 17 Months on Stem-Cell Study

Pluristem Therapeutics Inc. (PSTI), the Israeli developer of stem-cell therapies, rose the most in more than 17 months after an experimental treatment showed promise in a study of 20 patients with muscle injuries.

The stock surged 22 percent to 16.18 shekels ($4.63) at 11:04 a.m. in Tel Aviv. Earlier it gained as much as 27 percent, the biggest increase since Aug. 6, 2012. The shares fell 15 percent yesterday ahead of the study results.

The early-stage clinical trial assessing Pluristems placental-expanded, or PLX-PAD, cells in people who had a buttock muscle injured during hip-replacement surgery found the treatment was safe, the company said in a statement today. Patients getting the injection also fared better in a muscle-contraction exercise six months later.

These are remarkable results that signal advances in the cell-therapy industry, Jason Kolbert, an analyst with Maxim Group LLC in New York, said at a press conference organized by Pluristem in Tel Aviv.

The study results suggest the stem-cell therapy could help treat a broader range of muscle and tendon injuries, according to the Haifa-based company. We intend to move forward with implementing our strategy towards using PLX cells in orthopedic indications and muscle trauma, Chief Executive Officer Zami Aberman said in the statement.

The results come after the U.S. Food and Drug Administration in June placed one of Pluristems most advanced studies on hold after a patient suffered an allergic reaction. The hold was lifted in September.

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

Link:
Pluristem Gains Most in 17 Months on Stem-Cell Study

Inhaled Stem Cells Might Replace Lost Neurons

See Inside

Intranasal stem cell therapy may one day treat brain disorders

Image: Jim Kopp

Many diseases of the central nervous system involve the death of neuronsso, theoretically, the replacement of dead cells should improve symptoms of degenerative disorders such as Parkinson's, Huntington's, amyotrophic lateral sclerosis (ALS) and Alzheimer's, as well as stroke and brain tumors. Stem cell therapy may do just that even though evidence of its effectiveness is mixed.

In any cell transplant procedure, the host organin this case, the brainmay reject its new additions. Further, it is unclear whether grafted cells can truly integrate into complex neural circuitry. Finally, current procedures require invasive surgical implantation, which can be expensive and risky. The surgery can cause neural inflammation, and the implanted cells may quickly die.

Intranasal administration may address at least some of these issues. Most important, it eliminates the need for surgery. Further, some research suggests that stem cells delivered intranasally are smartthey do not spread through the brain indiscriminately but instead target damaged cells.

Although it is difficult to predict when medical practice will adopt stem cell therapy for the brain, animal studies have produced some promising results. In a rat model of Parkinson's, for example, treatment with intranasal stem cells appeared to improve motor function and slow the neurological deterioration associated with the disease.

2014 Scientific American, a Division of Nature America, Inc.

View Mobile Site All Rights Reserved.

Give a 1 year subscription as low as $14.99

Continued here:
Inhaled Stem Cells Might Replace Lost Neurons

Art imitating life: Cancer center fetes sculptor whose work is now permanently featured

Click photo to enlarge

A sculpture by Jan Martin Bopp sits center-stage at its unveiling party in the Southwestern Vermont Regional Cancer Center Wednesday. Bopp, a volunteer and cancer survivor, created the sculpture to symbolize his battle with myeloma. (Derek Carson)

A sculpture by Jan Martin Bopp sits center-stage at its unveiling party in the Southwestern Vermont Regional Cancer Center Wednesday. Bopp, a volunteer and cancer survivor, created the sculpture to symbolize his battle with myeloma. (Derek Carson)

BENNINGTON - The Southwestern Vermont Regional Cancer Center honored and celebrated local educator, sculptor, and volunteer Jan Martin Bopp on Wednesday.

Bopp was diagnosed with multiple myeloma, a cancer of plasma cells in which collections of abnormal plasma cells accumulate in bone marrow, where they interfere with the production of normal blood cells. Throughout his battle with cancer, he was also challenged with cardiovascular dysfunctions, a stem-cell transplant, chemotherapy, coronary artery stent implants, a carotid endarterectomy, a pacemaker implant, and what one speaker called the worst case of shingles he had ever seen.

Yet Bopp persevered through everything, and eventually decided to create a sculpture to symbolize his battle with myeloma. The result was "My Medical Journey: Trauma to Transcendence," a 17-inch wide, 16-inch tall, and 10-inch deep ceramic sculpture, which is on permanent display in the atrium of the cancer center.

The sculpture, which was completed in 2009, "embodies the story of my journey through extensive medical trauma and treatment to better health and a life coping with chronic illness," said Bopp in a written description that was displayed next to the sculpture. "It is a story of some of my physiological ambushes and health challenges and how I have responded, with much professional help, medicine and procedures, fortitude, and good fortune."

Bopp was born and raised near Lansing, Mich., completed his undergraduate studies at Hope College in Holland, Mich., and worked toward a graduate degree at Miami University of Ohio. In the 1970s he began teaching at Mount Greylock High School in Williamstown, Mass.

"My sculpture is a therapeutic expression of my resilience, positive energy and spirit, and eternal optimism. It has been given to the Southwestern Vermont Regional Cancer Center to symbolize my deep gratitude for the profound help of expert health care providers and to inspire others afflicted with cancer," said Bopp.

While 92 people officially RSVP'd to Wednesday's reception, the total number of attendees may very well have been higher. "Certainly tonight's turnout is a reflection of the impact Jan has made on all of us, on our lives," said Thomas Dee, CEO of Southwestern Vermont Health Care.

Go here to read the rest:
Art imitating life: Cancer center fetes sculptor whose work is now permanently featured

Stem Cell Clinics USA | Stem Cell Treatment

Stem Cells....Snake Oil or Reality?

Searching for stem cell treatment online will give you a huge number of results often offering unproven, and ill-explained, therapies at overseas clinics. Finding a clinic that offers such services in the US is nigh on impossible as the FDA controls the use of stem cells for both research and therapeutic application very carefully. To some this is a problem because it necessarily slows down the rate of availability of treatments, but for others it can, quite literally, save their lives. Whatever problems the FDA has, you can be pretty confident that undergoing stem cell treatment in the US means having a dedicated, experienced, and professional team of qualified scientists and doctors administering the treatment and handling follow-up care as appropriate. You can also be fairly sure that the stem cell treatments you undergo will have been researched professionally and reviewed extensively before being made available to patients.

Clinics overseas are often unregulated or so transient that they simply move from country to country as the authorities catch up with them. The staff at such clinics may well be highly regarded doctors or scientists who are practicing therapies they feel should be made available to all patients in the US now rather than when the FDA decides they are appropriate. However, in many cases these clinics are more concerned with convincing vulnerable patients to part with their money for treatments that are unlikely to offer any health benefits other than a placebo effect and may in fact be downright dangerous.

Controls on health, hygiene, and safe medical practices may not be followed in countries where the government turns a blind eye to such health tourism. Treatments using embryonic stem cells have been, and still are being used in clinics overseas despite safety concerns regarding the uncontrolled differentiation of these stem cells once injected into the body. The origins of such biological material is also questionable in many cases with the Ukraine implicated, a number of years ago, in a scandal involving dubious procurement of foetuses and infants for stem cell therapies.

Clinical trials exist not in order to frustrate patients awaiting treatment but to safeguard patients from potentially dangerous and mishandled therapy. Even after clinical trials have been carried out and a treatment approved there are still many potential problems that can arise in the much larger number of patients treated than those in the trials themselves. Clinical trials can at least avoid some of the more overt contraindications and highlight the need for further research. They also allow patients to receive treatments which are likely to be efficacious and can be covered by medical insurance.

Travelling overseas for treatments often means invalidating the health-care plan in the US and any complications (such as infection, tumor growth, or paralysis) requiring further treatment or hospitalization when back home are often excluded from such plans. Although many clinics in the US offer stem cell treatments the reality is that patients only have their consultation on US soil and then must travel to a clinic in the Caribbean, Ukraine or other country to actually undergo the treatment as it is not approved by the FDA.

Research trials conducted overseas may offer patients a way of accessing treatment but these should be approached cautiously as the regulation of standards in such trials can vary widely. Again, some researchers are perfectly professional and are simply looking to further the field of regenerative medicine without having to adhere to the seemingly overly stringent restrictions put in place by US regulators. Others however, are adept at engaging in methodologically unsound trials which prove to be little more than anecdotal observation and publishing these in a non-peer-reviewed trade journal of their own making. Claiming that a therapy has been proven to work and has had research published to such effect means very little unless the journal, the paper, and the raw data are readily available for other scientists to review and confirm through repeated experiment.

Stem Cell Treatment overseas is often unregulated and downright dangerous

Clinics in Russia, India, Mexico, and Panama are offering treatments with little, if any, clinical evidence to merit their use. Even in the US there are doctors who are using a loophole in regulations to treat patients with their own stem cells despite there being limited evidence proving any benefit from such treatment. These doctors extract stem cells from fatty tissue using liposuction and minimal processing techniques and then inject the stem cells back into the patient all in an outpatient procedure taking around seven hours or so. This treatment is unlikely to be harmful to a patient but is far from proven to be effective for any disease condition. Indeed, the clinics offering such treatment maintain that it is not intended to treat any pathology and is at best a cosmetic procedure. Clearly the establishment of such clinics and the marketing practices defies this supposed intention and is much more geared toward ill and vulnerable patients.

China, well known for offering stem cell treatments to patients despite a lack of evidence for safety or efficacy, passed a law last May requiring clinical trials prior to such treatments being offered to patients. The degree to which this law is being enforced remains unknown, and, as yet, there have been no public announcements of clinics shut down under the new regulations. There are thought to be around 150 clinics in China which offer stem cell therapy for conditions ranging from spinal cord injuries to Multiple Sclerosis, and diabetes. Patients from the US would expect to pay around $25,000 for treatments in Chinese stem cell clinics although the cost of follow-up treatments and possible rehabilitative care in the US is not included in this price.

Read this article:
Stem Cell Clinics USA | Stem Cell Treatment

New Assessment Tool Shows Potential of Stem Cells in Restoring LSCD Patients’ Sight

Durham, NC (PRWEB) January 17, 2014

A new assessment tool is helping scientists determine which treatments might benefit patients with a type of eye disorder called limbal stem cell deficiency (LSCD). The tool, developed by researchers at University College London and Moorfields Eye Hospital in London and funded by the UKs National Institute for Health Research Biomedical Research Centre at these institutions, has already shown that the majority of these patients can benefit in the short term from a stem cell transplantation and up to 30 percent are still experiencing better sight three years later, according to the study published in the current issue of STEM CELLS Translational Medicine.

LSCD is an eye disorder in which the stem cells responsible for forming the surface skin of the cornea are destroyed by injury or disease. This results in pain, loss of vision and a cosmetically unpleasant appearance. Many new treatments, including limbal stem cell transplants, are emerging for this condition but their effectiveness remains to be proven.

Assessing how well they perform has been severely hampered by the lack of biomarkers for LSCD and/or validated tools for determining its severity, said Alex Shortt, M.D., Ph.D., of University College Londons Institute of Ophthalmology and lead investigator in the study. In virtually all studies of limbal stem cell transplantation to date the clinical outcome has been assessed subjectively by the investigating clinician. This is clearly open to significant measurement and reporting bias.

His teams aims, then, were to design and test the reliability of a new tool for grading LSCD, to define a set of core outcome measures to use in evaluating treatments and to demonstrate the treatments impact on two common types of LSCD: a genetic disorder called aniridia and Stevens-Johnson syndrome (SJS), an inflammatory disorder.

They began developing an assessment tool by paring down a list of clinical signs taken from previously published studies to four key LSCD indicators: corneal epithelial haze, superficial corneal neovascularization, corneal epithelial irregularity and corneal epithelial defect. A standardized grading plate was then produced for each of these parameters, ranging from normal to severe. They named their assessment method the Clinical Outcome Assessment in Surgical Trials of Limbal stem cell deficiency [COASTL] tool and validated its performance in 26 patients with varying degrees of LSCD.

Once they had the COASTL tool in place, they used it to evaluate treatment outcomes in 14 patients with aniridia or SJS. All had undergone a limbal epithelial transplantation (allo-CLET), using cells taken from a deceased donor, cultivated in the lab before being transplanted into the recipient.

The COASTL tool showed that following allo-CLET there was a decrease in LSCD severity and an increase in visual acuity up to 12 months post-treatment, but thereafter LSCD severity and visual acuity progressively deteriorated, Dr. Shortt said. However, despite a recurrence of clinical signs, the visual benefit persisted in 30 percent of aniridic and 25 percent of SJS patients at 36 months.

A reliable method of obtaining objective outcome data for surgical trials of limbal stem cell deficiency will greatly contribute to the effective evaluation of current and new treatments, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

The full article, Three-Year Outcomes of Cultured Limbal Epithelial Allografts in Aniridia and Stevens-Johnson Syndrome Evaluated Using the Clinical Outcome Assessment in Surgical Trials Assessment Tool, can be accessed at http://www.stemcellstm.com.

See the original post here:
New Assessment Tool Shows Potential of Stem Cells in Restoring LSCD Patients’ Sight

SmartChoice® Adult Stem Cell Procedures – Incredible pain relief in just one treatment – Video


SmartChoice Adult Stem Cell Procedures - Incredible pain relief in just one treatment
Patient Testimonial: Donna was a patient with severe knee and back pain. After just one treatment at SmartChoice, her life has significantly improved. Learn...

By: Hardesh Garg

Read more here:
SmartChoice® Adult Stem Cell Procedures - Incredible pain relief in just one treatment - Video